Local site recurrence after radiofrequency ablation of colorectal liver metastases
Conditions
Interventions
None listed
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Histological or cytological documentation of primary colorectal tumor Radiological or histological prove of one or more CRLM or radiological prove of a LSR after previous RFA/MWA treatment for CRLM CRLM or LSR treated with RFA/MWA or RFA/MWA in combination with resection Follow-up imaging performed in VUmc medical centre Age ³ 18 years Life expectancy of at least 1 year eGFR > 60 or hydration according to protocol before scanning
Exclusion criteria
Exclusion criteria: Cirrosis or steatosis Chemotherapy * 6 weeks before scanning (during the entire study) Pregnant or breast-feeding subjects Allergy to contrast media Patients developing recurrent intrahepatic disease that require resection of the ablated lesion eGFR
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is the ability of PET-MRI in the detection of LSR in the liver compared to ceCT of the liver and PET-CT referred to histological findings or clinical follow-up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are the inter-observer variability, the ability to diagnose new intrahepatic lesions and in what way PET-MRI is able to influence future treatment compared to PET-CT and ceCT. The patients satisfaction concerning the PET-MRI will be examined with a questionnaire. | — |
Countries
Netherlands
Outcome results
None listed